Search the Newsreel

38,495 Shares in Harley-Davidson, Inc. $HOG Acquired by State of Wyoming

The State of Wyoming acquired 38,495 shares of Harley-Davidson, Inc. (NYSE:HOG) in the second quarter, valued at approximately $942,000. Institutional investors now own 85.10% of the company, and analysts generally maintain a "Hold" rating with an average price target of $26.11. Harley-Davidson recently exceeded …

BioMarin Pharmaceutical (BMRN) Updates Guidance And Files Shelf Registration, Is It Still Below Fair Value?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. BioMarin Pharmaceutical (BMRN) has just given investors a packed update, including second quarter 2026 results, fresh earnings guidance for the rest of the …

S&CO Inc. Acquires Shares of 26,139 Linde PLC $LIN

S&CO Inc. has acquired a new position in Linde PLC (NASDAQ:LIN), purchasing 26,139 shares valued at approximately $13.56 million in the second quarter. Other institutional investors have also modified their holdings, with hedge funds and institutional investors collectively owning 82.80% of Linde's stock. Linde …

S&CO Inc. Buys Shares of 358,302 Royalty Pharma PLC $RPRX

Nicolet Bankshares Inc. $NIC Shares Purchased by Russell Investments Group Ltd.

SFE Investment Counsel Invests $6.91 Million in L3Harris Technologies Inc $LHX

SFE Investment Counsel has acquired a new stake of $6.91 million in L3Harris Technologies Inc, purchasing 23,782 shares during the second quarter. The company reported strong quarterly earnings of $3.13 per share, exceeding estimates, with an 8.4% rise in revenue. L3Harris also declared a …

USA Financial Formulas Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN

USA Financial Formulas has acquired a new stake in Regeneron Pharmaceuticals (NASDAQ:REGN), purchasing 1,457 shares valued at approximately $1.13 million, making it their 27th-largest portfolio holding. Institutional investors collectively own 83.31% of Regeneron, with several major firms significantly increasing their positions. The company recently …

ArriVent BioPharma (AVBP) Could Be 56% Undervalued After The Allist China Licensing Deal

BridgeBio Pharma (BBIO) Secured Two Priority Reviews For Rare Disease Drugs

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. BridgeBio Pharma (NasdaqGS:BBIO) reports recent clinical and regulatory milestones across late-stage rare disease assets, including acoramidis, BBP-418, and encaleret. Acoramidis continues to show differentiated …

Is Ionis Pharmaceuticals (IONS) Undervalued Following Its Pullback?

Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ionis Pharmaceuticals stock carries a strong three year return record alongside a high overall value score, yet current market multiples still point to the shares …

Harmony Biosciences Holdings (HRMY), Why Is It Getting Fresh Attention?

Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts

Phathom Pharmaceuticals (PHAT) has experienced a modest fair value cut from US$23.70 to US$21.50 following analyst target revisions. This adjustment is due to updated Q2 results, revised 2026 revenue guidance, and new perspectives on their drug Voquezna's commercial path. While some firms remain bullish …

Interest paid of Charles Schwab Corp Shs Cert Deposito Arg Repr 0.0769230769 Shs – BCBA:SCHW.CI

This article provides financial information, specifically "Interest paid," for Charles Schwab Corp Shs Cert Deposito Arg Repr 0.0769230769 Shs under the ticker BCBA:SCHW.CI on the Buenos Aires Stock Exchange. The information is presented within the TradingView platform, detailing market status and offering various analytical …

Should I buy Agencia Comercial Spirits Ltd (AGCC)

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Brokerages

Tarsus Pharmaceuticals (NASDAQ:TARS) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $90.50, significantly higher than its current share price of $69.20. The company recently reported quarterly revenue of $173.91 million, surpassing estimates, but its loss per …

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination

Citius Pharmaceuticals reported promising early results for its approved drug LYMPHIR in new indications, including an 86% objective response rate in a Phase 1 CAR-T combination trial for diffuse large B-cell lymphoma and a 24% ORR in gynecologic malignancies. The company also announced strong …

Oddity Tech (ODD) Stock Gets Fair Value Bump After Cautious Analyst Revisions

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Oddity Tech's modeled fair value has shifted from US$10.25 to about US$11.07, signaling a modest recalibration in where some analysts see the stock's …

Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative?

Mirum Pharmaceuticals reported a significant net loss for Q2 and H1 2026, with basic loss per share rising, which highlights increased costs relative to revenue. This widening loss intensifies focus on cash burn and funding risks, despite upcoming clinical and regulatory catalysts such as …

Wall Street Zen Downgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Sell

Wall Street Zen has downgraded Mirum Pharmaceuticals (NASDAQ:MIRM) from "hold" to "sell," despite the company reporting better-than-expected quarterly revenue of $176.24 million, a 37.9% increase year-over-year. The downgrade comes as the company missed earnings per share estimates, reporting a loss of $1.06 against a …

Responsive Playbooks and the ETON Inflection

This article provides an AI-driven analysis for Eton Pharmaceuticals Inc. (NASDAQ: ETON), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details specific trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The report suggests …

Wall Street Zen Upgrades Home BancShares (NYSE:HOMB) to Hold

Wall Street Zen has upgraded Home BancShares (NYSE:HOMB) from a "sell" to a "hold" rating, aligning with the overall analyst sentiment of "Hold." The company recently reported strong quarterly earnings, exceeding estimates with an EPS of $0.64 and revenue of $295.1 million, an 8.9% …

Harmony Biosciences (NASDAQ:HRMY) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen has upgraded Harmony Biosciences (NASDAQ:HRMY) from a "buy" to a "strong-buy" rating. This upgrade comes as the company reported strong quarterly earnings, beating analyst estimates with an EPS of $1.28 and a 30.3% year-over-year revenue increase to $261.28 million. Despite this, …

Rigel Pharmaceuticals (RIGL) Stock Sees Fair Value Lift As Veppanu Launch Adds Growth Hope

Rigel Pharmaceuticals (RIGL) has seen its fair value estimate increase from US$51.6 to US$61.2 per share, primarily due to the launch of Veppanu in the U.S. and the international potential of Rezlidhia through a partnership with Kissei. Analysts, such as H.C. Wainwright, view Veppanu …

Why Eton Pharmaceuticals (ETON) Is Up 32.0% After Q2 Earnings Surge And Raised 2026 Outlook

Eton Pharmaceuticals (ETON) saw its stock rise 32.0% after reporting a significant Q2 2026 earnings turnaround, with revenue surging to US$37.59 million and net income reaching US$11.58 million. The company also raised its full-year 2026 revenue guidance to at least US$145 million and expanded …

Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – DUS:1RV

This article provides financial data for Rhythm Pharmaceuticals, Inc. (DUS:1RV) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to revenue forward. It notes that the market is closed with no trades recorded at the time of publication. The content is presented …

Marksans Pharma Limited (NSE:MARKSANS) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Santacruz Silver Mining (TSXV:SCZ) Stock Rallies Into A Sharp Profit Squeeze

Santacruz Silver Mining (TSXV:SCZ) saw its stock rally significantly before a sharp profit squeeze in Q2 2026. Despite a large revenue increase year-over-year, net income and basic EPS dropped by approximately 90-91%, raising questions about the resilience of its earnings momentum. This quarter's results …

ETFs Investing in Iperionx Ltd. Sponsored ADR Stocks

This article lists several ETFs that invest in Iperionx Ltd. Sponsored ADR stocks, providing details such as market value, weight, issuer, management style, expense ratio, and AUM for each fund. The funds aim to make investing in stocks more accessible and offer diversified opportunities …

Does VinFast (VFS) Risk Overreliance On Vietnam As Its EV Growth Platform Strengthens?

VinFast Auto Ltd. reported a 21% increase in EV deliveries in Vietnam in July 2026, reaching 21,781 units and reinforcing its leadership in the local market. While this domestic strength supports VinFast's ambitious global EV delivery target for 2026, it also highlights a potential …

Is Pony AI (PONY) Undervalued Following Its Uber Robotaxi Expansion Plan?

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Pony AI (PONY) stock is in focus after the company and Uber announced plans to deploy more than 2,000 Pony.ai Robotaxis across Europe, …

Enterprise value to revenue forward of Oyster Enterprises II Acquisition Corp – NASDAQ:OYSER

This article briefly mentions the enterprise value to revenue forward for Oyster Enterprises II Acquisition Corp (NASDAQ: OYSER). It appears to be a stub or a placeholder for financial data related to the company, indicating a specific period and value for this metric. The …

Charter Stock Outlook: Can the $34.5B Cox Merger Help CHTR Recover Before Earnings?

Vanguard's VGLT or Schwab's SCHQ: Which Long-Term Treasury ETF Is the Better Buy?

The Vanguard Long-Term Treasury ETF (NASDAQ:VGLT) and the Schwab Long-Term U.S. Treasury ETF (NYSEMKT:SCHQ) provide near-identical exposure to long-duration government debt with matching expense ratios and performance profiles. Both the Vanguard fund and the Schwab fund target the long end of the U.S. Treasury …

Which Is the Better Dividend ETF: Schwab's Defensive SCHD or Fidelity's Tech-Tilted FDVV?

The Schwab U.S. Dividend Equity ETF (NYSEMKT:SCHD) offers a lower-cost, lower-volatility approach compared to the Fidelity High Dividend ETF (NYSEMKT:FDVV), which leans heavily into growth-oriented sectors like technology and financial services. Income investors often choose between high current yield and long-term growth potential. While …

Did Rocketdyne Spin-Off and Undersea Expansion Just Shift L3Harris Technologies' (LHX) Investment Narrative?